HRP20170471T1 - Spojevi piperazin-piperidina kao inhibitori hepatitis c virusa - Google Patents
Spojevi piperazin-piperidina kao inhibitori hepatitis c virusa Download PDFInfo
- Publication number
- HRP20170471T1 HRP20170471T1 HRP20170471TT HRP20170471T HRP20170471T1 HR P20170471 T1 HRP20170471 T1 HR P20170471T1 HR P20170471T T HRP20170471T T HR P20170471TT HR P20170471 T HRP20170471 T HR P20170471T HR P20170471 T1 HRP20170471 T1 HR P20170471T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- optionally substituted
- hydrogen
- compound
- 3alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637959P | 2012-04-25 | 2012-04-25 | |
| US201361774033P | 2013-03-07 | 2013-03-07 | |
| EP13720201.6A EP2850075B1 (en) | 2012-04-25 | 2013-04-24 | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
| PCT/US2013/037920 WO2013163262A1 (en) | 2012-04-25 | 2013-04-24 | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170471T1 true HRP20170471T1 (hr) | 2017-06-02 |
Family
ID=48237291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170471TT HRP20170471T1 (hr) | 2012-04-25 | 2013-04-24 | Spojevi piperazin-piperidina kao inhibitori hepatitis c virusa |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9206159B2 (https=) |
| EP (1) | EP2850075B1 (https=) |
| JP (1) | JP6069491B2 (https=) |
| CN (1) | CN104302639B (https=) |
| CA (1) | CA2869640C (https=) |
| CY (1) | CY1118920T1 (https=) |
| DK (1) | DK2850075T3 (https=) |
| ES (1) | ES2624846T3 (https=) |
| HR (1) | HRP20170471T1 (https=) |
| HU (1) | HUE032173T2 (https=) |
| LT (1) | LT2850075T (https=) |
| ME (1) | ME02682B (https=) |
| PL (1) | PL2850075T3 (https=) |
| PT (1) | PT2850075T (https=) |
| RS (1) | RS55864B1 (https=) |
| SI (1) | SI2850075T1 (https=) |
| WO (1) | WO2013163262A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108794454B (zh) * | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | 一种咪唑环化合物的制备方法 |
| CN107814789B8 (zh) * | 2017-11-27 | 2021-01-01 | 常州寅盛药业有限公司 | 一种达卡他韦起始原料的合成方法 |
| CN121816348A (zh) | 2023-08-11 | 2026-04-07 | 深圳众格生物科技有限公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PT3309157T (pt) | 2009-05-13 | 2019-12-02 | Gilead Pharmasset Llc | Compostos antivirais |
| EA201290089A1 (ru) | 2009-09-04 | 2012-09-28 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Химические соединения |
| EP2475254A4 (en) * | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011079327A1 (en) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| EA201290882A1 (ru) | 2010-03-09 | 2013-04-30 | Мерк Шарп Энд Домэ Корп. | Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний |
| EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| CA2814534A1 (en) | 2010-11-04 | 2012-05-10 | Theravance, Inc. | Novel inhibitors of hepatitis c virus |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN103946220B (zh) | 2011-11-03 | 2017-12-22 | 施万生物制药研发Ip有限责任公司 | 含有片段{2‑[4‑(联苯‑4‑基)‑1h‑咪唑‑2‑基]吡咯烷‑1‑羰基甲基}胺的杆状丙型肝炎病毒抑制剂 |
| EP2850072B1 (en) * | 2012-04-25 | 2016-08-31 | Theravance Biopharma R&D IP, LLC | Hepatitis c virus inhibitors |
-
2013
- 2013-04-24 HU HUE13720201A patent/HUE032173T2/en unknown
- 2013-04-24 WO PCT/US2013/037920 patent/WO2013163262A1/en not_active Ceased
- 2013-04-24 ES ES13720201.6T patent/ES2624846T3/es active Active
- 2013-04-24 HR HRP20170471TT patent/HRP20170471T1/hr unknown
- 2013-04-24 PL PL13720201T patent/PL2850075T3/pl unknown
- 2013-04-24 EP EP13720201.6A patent/EP2850075B1/en active Active
- 2013-04-24 US US13/869,199 patent/US9206159B2/en not_active Expired - Fee Related
- 2013-04-24 LT LTEP13720201.6T patent/LT2850075T/lt unknown
- 2013-04-24 DK DK13720201.6T patent/DK2850075T3/en active
- 2013-04-24 ME MEP-2017-85A patent/ME02682B/me unknown
- 2013-04-24 CA CA2869640A patent/CA2869640C/en not_active Expired - Fee Related
- 2013-04-24 RS RS20170354A patent/RS55864B1/sr unknown
- 2013-04-24 JP JP2015509099A patent/JP6069491B2/ja not_active Expired - Fee Related
- 2013-04-24 SI SI201330640A patent/SI2850075T1/sl unknown
- 2013-04-24 CN CN201380021717.8A patent/CN104302639B/zh not_active Expired - Fee Related
- 2013-04-24 PT PT137202016T patent/PT2850075T/pt unknown
-
2017
- 2017-05-17 CY CY20171100520T patent/CY1118920T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2624846T3 (es) | 2017-07-17 |
| CA2869640C (en) | 2018-03-20 |
| JP2015514807A (ja) | 2015-05-21 |
| SI2850075T1 (sl) | 2017-06-30 |
| CY1118920T1 (el) | 2018-01-10 |
| PL2850075T3 (pl) | 2017-08-31 |
| HUE032173T2 (en) | 2017-09-28 |
| CN104302639A (zh) | 2015-01-21 |
| US9206159B2 (en) | 2015-12-08 |
| EP2850075B1 (en) | 2017-02-22 |
| US20130287730A1 (en) | 2013-10-31 |
| ME02682B (me) | 2017-06-20 |
| CA2869640A1 (en) | 2013-10-31 |
| EP2850075A1 (en) | 2015-03-25 |
| CN104302639B (zh) | 2017-03-29 |
| DK2850075T3 (en) | 2017-05-22 |
| PT2850075T (pt) | 2017-05-02 |
| LT2850075T (lt) | 2017-05-10 |
| WO2013163262A1 (en) | 2013-10-31 |
| RS55864B1 (sr) | 2017-08-31 |
| JP6069491B2 (ja) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| ME02875B (me) | Inhibitori hcv polimeraze | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| RU2014122340A (ru) | Ингибиторы вируса гепатита с, имеющие жесткую вытянутую цепь и содержащие фрагмент {2-[4-(бифенил-4-ил)-1н-имидазо-2-ил]пирролидин-1-карбонилметил}амина | |
| HRP20220920T1 (hr) | Pirolo[1,2-f][1,2,4]triazini koji su korisni za liječenje infekcija respiratornim sincicijalnim virusom | |
| JP2011079828A5 (https=) | ||
| JP2013521279A5 (https=) | ||
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| HRP20241540T1 (hr) | Pirolotriazinski spojevi koji djeluju kao inhibitor mnk | |
| HRP20180746T4 (hr) | Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| AR073760A1 (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| HRP20160623T1 (hr) | Inhibitori proteinske kinaze | |
| AR059481A1 (es) | Derivados de 1, 3-dihidro-imidazo[4, 5-c]piridin-2-ona como agonista del receptor tlr7, un metodo para su preparacion, intermediarios de sintesis de los mismos, una composicion farmaceutica que los comprende y su uso en la elaboracion de un medicamento para el tratamiento de infecciones viricas. | |
| HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| JP2013514359A5 (https=) | ||
| RU2015123641A (ru) | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний | |
| HRP20220628T1 (hr) | Postupci i međuprodukti za pripremu lijeka | |
| JP2013529196A5 (https=) | ||
| ME02656B (me) | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje | |
| ME02566B (me) | Derivati imidazopiridazina kao modulatori receptora gabaa | |
| HRP20180483T1 (hr) | Spoj kinolona |